ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 930

The Endocannabinoid Anandamide Modulates Adhesion, Proliferation and The Production Of Inflammatory Mediators In Rheumatoid Arthritis Synovial Fibroblasts By Activating CB1, TRPV1, TRPA1 and Non-Cannabinoid Receptor Targets

Torsten Lowin, Angelika Graeber and Rainer H. Straub, Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adhesion molecules, cannabinoid, cytokines and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) secrete large amounts of IL-6, IL-8 and matrix metalloproteinases (MMPs) which are crucial for cartilage destruction. RASFs are sensitive to the action of cannabinoids and they express cannabinoid receptors type I and II (CB1 and CB2), the vanilloid receptor (TRPV1) as well as endocannabinoid degrading enzymes (FAAH and COX-2). Cannabinoids are regarded as antiinflammatory and since anandamide (AEA) is found in RA synovial fluid we investigated how this endocannabinoid affects adhesion, proliferation and production of inflammatory mediators of RASF.

Methods: Adhesion was assessed by the XCELLigence system. Proliferation was quantified by the amount of incorporated fluorescent dye into cellular DNA. MMP-3 and cytokines were detected by ELISA. Collagen II induced arthritis was used a s a mouse model of RA.

Results:   AEA dose-dependently decreased IL-1β induced production of MMP-3, IL-6 and IL-8 in RASFs and OASFs under normoxic conditions (20% O2). The efficacy of AEA was significantly enhanced by addition of the COX-2 inhibitor nimesulide. The effects of AEA were not inhibited by CB1, CB2 or GPR55 antagonists but were blocked by the TRPV1 antagonist capsazepine in RASFs but not OASFs.  Under hypoxic conditions (1% O2) and TNF stimulation, the effects of AEA on cytokine and MMP-3 production were blocked by TRPA1 and TRPV1 antagonists.In mixed synovial cell cultures however, AEA increased the production of TNF (100%) which was enhanced by inhibition of AEA degradation.Furthermore, AEA increased adhesion of OASFs and RASFs to fibronectin. Adhesion was modulated by CB1, GPR55, and TRPV1 antagonists in OASFs but not in RASFs. Combined FAAH and COX-2 inhibition blocked the stimulatory effect of AEA on adhesion in OASF. Proliferation was decreased by AEA in RASFs and OASFs via a cyclooxygenase-2 but not via CB1, CB2 or TRPV1 dependent mechanism.Elevation of endogenous AEA by inhibition of its degradation showed beneficial effects in collagen-induced arthritis in mice.

Conclusion: In conclusion, AEA promotes an antiinflammatory phenotype of RASFs and OASFs by activating/desensitizing TRPV1 and TRPA1 under hypoxic conditions. Furthermore, COX-2 inhibition is necessary to fully exploit the therapeutic potential of AEA. This might be important in RA where low oxygen and abundant cytokine expression up-regulate COX-2 in the joint.


Disclosure:

T. Lowin,
None;

A. Graeber,
None;

R. H. Straub,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-endocannabinoid-anandamide-modulates-adhesion-proliferation-and-the-production-of-inflammatory-mediators-in-rheumatoid-arthritis-synovial-fibroblasts-by-activating-cb1-trpv1-trpa1-and-non-canna/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology